TNF-alpha inhibitors: Current indications

Indian Journal of Critical Care Medicine

Volumn 11, Issue 3, 2007, Pages 139-148

  Sharma, Rashmi ^a,c   Sharma, Chaman ^b  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b UN Mission Congo (Monuc)   (India)

^c NONE   (India)

Author keywords

Adalimumab; Ankylosing spondylitis; Etanercept; Infliximab; Psoriasis; Rheumatoid arthritis; Tuberculosis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALCOHOL LIVER DISEASE; ANKYLOSING SPONDYLITIS; ASTHMA; ATOPIC DERMATITIS; BEHCET DISEASE; BRAIN MALARIA; BULLOUS DERMATITIS; CANCER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG HALF LIFE; DRUG SURVEILLANCE PROGRAM; ERYTHEMA NODOSUM; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INDIA; MYELODYSPLASTIC SYNDROME; OTITIS MEDIA; POLYMYOSITIS; PREECLAMPSIA; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULE; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SNAKEBITE; SYSTEMIC VASCULITIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; ULCERATIVE COLITIS; UVEITIS;

EID: 35148896762     PISSN: 09725229     EISSN: None     Source Type: Journal    
DOI: 10.4103/0972-5229.35087     Document Type: Review

References (47)

1. Mahajan A, Sharma R, Khajuria R, et al. Rheumatoid arthritis: New developments in biologic therapy. J Indian Med Assoc 2006;104:327-30.
2. Mahajan A, Sharma R, Singh JB. Biological therapy in Rheumatoid Arthritis: Current status. Indian J Rheumatol 2006;1:13-9.
3. Arya V. Food and drug administration (FDA) approval status of biologicals used in Rheumatology. Indian J Rheumatol 2006;1:41.
4. Waknine Y. FDA approvals: Duetact and humira. Medscape family medicine/primary care MedPulse® release. Available from: http:// www.medscape_familymed@mp.medscape.com. [Last accessed on 2006 Aug 9].
5. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with Rheumatoid Arthritis (update of previous guidelines of April 2001). Rheumatol 2005;44:157-63.
6. Singh J, Suruchi A. Anti-TNF-α strategy: Present status of this therapeutic paradigm. Indian J Pharmacol 2004;36:10-4.
7. Boulos P, Dougados M, Macleod SM, Hunsche E. Pharmacological treatment of ankylosing spondylitis: A systematic review. Drugs 2005;65:2111-27.
8. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
9. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicentre trial. Lancet 2002;359:1187-93.
10. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
11. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
12. Schachna L. The anti-TNF revolution in ankylosing spondylitis. Med J Am 2004;181:529-30.
13. Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis 2005;20:1-8.
14. Siddiqui MA, Scott LJ. Spotlight on infliximab in Crohn disease and rheumatoid arthritis. BioDrugs 2006;20:67-70.
15. Sandborn WJ. Transcending conventional therapies: The role of biologic and other novel therapies. Inflamm Bowel Dis 2001;1: S9-16.
16. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004;1:CD003574.
17. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
18. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004;8:231-3.
19. Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomized controlled trial. Gut 2003;52:998-1002.
20. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
21. Antoni C, Manger B. Treatment of psoriatic arthritis with TNF alpha-antagonists. J Rheumatol 2003;62:235-9.
22. Behnam SM, Behnam SE, Koo JY. TNF-alpha inhibitors and congestive heart failure. Skinmed 2005;4:363-8.
23. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000;356:385-90.
24. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
25. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
26. Little MA, Bhangal G, Smyth CL, Nakada MT, Cook HT, Nourshargh S, et al. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006;17:160-9.
27. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52:522-6.
28. Henriksen PA, Newby DE. Therapeutic inhibition of tumor necrosis factor- in patients with heart failure: Cooling an inflamed heart. Heart 2003;89:14-8.
29. Chung ES, Packer M, Lo KH, et al. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
30. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis, preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12.
31. Vincent JL. Afelimomab. Int J Clin Pract 2000;54:190-3.
32. Howarth PH, Babu KS, Arshad HS, et al. Tumour Necrosis Factor (TNF) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax. Published Online First: 15 September 2005 doi:10.1136/thx.2005. 045260 © 2005 by BMJ Publishing Group Ltd and British Thoracic Society: [Last accessed on 2006 Dec 28].
33. Vincent JL. Afelimomab. Int J Clin Pract 2000;54:190-3.
34. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 2001;29:S121-5.
35. Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006;34:2484-5.
36. Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody Infliximab. Diabetes Care 2005;28:445-7.
37. Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, et al. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF- Inhibitors and GLP-1 Receptor agonists. Ann NY Acad Sci 2004;1035:290-315.
38. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: First experiences. Ann Rheum Dis 2001;60:iii55-7.
39. Narayanan K, Anand KP. Two year follow up of infliximab therapy in inflammatory arthritis. J Indian Rheumatol Assoc 2005;13:7-8.
40. Singh S, Sinal VK, Chaturvedi V. Strategy to prevent tuberculosis during anti TNF therapy in juvenile ankylosing- spondylitis with low dose infliximab without loading schedule: A one year open label study of toxicity and efficacy in 15 patients. J Indian Rheumatol Assoc 2005;13:5-6.
41. Kumar A. Experience with anti-tumor necrosis factor-α therapy in India. APLAR J Rheumatol 2006;9:136.
42. Sridhar J, Desylva P, Singh YD. Chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis. Indian J Dermatol Venereol Leprol 2006;72:133-5.
43. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatol (Oxford) 2005;44:1205-6.
44. Attri SK. Infliximab in spondyloarthropathy. Indian J Rheumatol 2006;14:37.
45. Grover R, Kapoor S, Marwaha V. Authors' reply. Indian J Rheumatol 2006;14:37-8.
46. Tandon VR, Mahajan A, Khajuria V. TNF blockers and tuberculosis: An Indian concern. Indian J Rheumatol 2006;1:66-71.
47. Mpofu S, Fatima F, Moots RJ. Anti-TNF-α therapies: They are all the same (aren't they?) Rheumatol 2005;44:271-3.